{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:57:06Z","timestamp":1790236626993,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10624-4","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:59:04Z","timestamp":1775789944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tailoring heart failure management in cardiac amyloidosis"],"prefix":"10.1007","volume":"31","author":[{"given":"Ernesto Ruiz","family":"Duque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos-lason","family":"Tepetes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kourek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9215-880X","authenticated-orcid":false,"given":"Ibrahim","family":"Mortada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamantia","family":"Papamichail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Stamatelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabea","family":"Asleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"4","key":"10624_CR1","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","volume":"18","author":"M Fontana","year":"2025","unstructured":"Fontana M, Ioannou A, Cuddy S, Dorbala S, Masri A, Moon JC et al (2025) The Last Decade in Cardiac Amyloidosis. JACC Cardiovasc Imaging 18(4):478\u2013499. https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10624_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","volume":"4","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar AD, Fontana M, Quarta CC, Liedtke M (2022) AL Amyloidosis for Cardiologists. JACC CardioOncol 4(4):427\u2013441. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.009","journal-title":"JACC CardioOncol"},{"issue":"12","key":"10624_CR3","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (Light-Chain) Cardiac Amyloidosis. J Am Coll Cardiol 68(12):1323\u20131341. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.053","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10624_CR4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D et al (2019) A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood 134(25):2271\u20132280. https:\/\/doi.org\/10.1182\/blood.2019000834","journal-title":"Blood"},{"issue":"12","key":"10624_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S (2016) AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol 68(12):1323\u20131341 06.053 PubMed PMID: 27634125","journal-title":"J Am Coll Cardiol"},{"key":"10624_CR6","doi-asserted-by":"publisher","unstructured":"Faria VS, Murad CM, Marcondes-Braga FG (2024) Heart failure management of patients with amyloid cardiomyopathy. Int J Cardiovasc Sci 37. https:\/\/doi.org\/10.36660\/IJCS.20240043","DOI":"10.36660\/IJCS.20240043"},{"key":"10624_CR7","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ et al (2020) Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 142(1). https:\/\/doi.org\/10.1161\/CIR.0000000000000792","DOI":"10.1161\/CIR.0000000000000792"},{"key":"10624_CR8","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.amjmed.2022.02.005","volume":"135","author":"P King","year":"2022","unstructured":"King P, Kates AM (2022) Management of Cardiac Symptoms in Amyloidosis. Am J Med 135:S9\u201312. https:\/\/doi.org\/10.1016\/j.amjmed.2022.02.005","journal-title":"Am J Med"},{"issue":"2","key":"10624_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cardfail.2024.08.046","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A et al (2025) Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America. J Card Fail 31(2):456\u2013463. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.046","journal-title":"J Card Fail"},{"issue":"2","key":"10624_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.36660\/abchf.20210033","volume":"1","author":"LC Danzmann","year":"2021","unstructured":"Danzmann LC, Zimmer JRC, Tscheika AP (2021) Heart failure with preserved ejection fraction and cardiac amyloidosis: implications for treatment. ABC: Heart Fail Cardiomyopathy 1(2):98\u2013102. https:\/\/doi.org\/10.36660\/abchf.20210033","journal-title":"ABC: Heart Fail Cardiomyopathy"},{"issue":"1","key":"10624_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cardiogenetics11010002","volume":"11","author":"F Iodice","year":"2021","unstructured":"Iodice F, Di Mauro M, Migliaccio M, Iannuzzi A, Pacileo R, Caiazza M et al (2021) Cardiac Amyloidosis Therapy: Syst Rev Cardiogenetics 11(1):10\u201317. https:\/\/doi.org\/10.3390\/cardiogenetics11010002","journal-title":"Cardiac Amyloidosis Therapy: Syst Rev Cardiogenetics"},{"issue":"4","key":"10624_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14740\/cr1664","volume":"15","author":"J Llerena-Velastegui","year":"2024","unstructured":"Llerena-Velastegui J, Zumbana-Podaneva K (2024) Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review. Cardiol Res 15(4):211\u2013222. https:\/\/doi.org\/10.14740\/cr1664","journal-title":"Cardiol Res"},{"issue":"2","key":"10624_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/HFJI.HFJI_34_23","volume":"1","author":"O Siddiqi","year":"2023","unstructured":"Siddiqi O, Gopal D, Ruberg F (2023) Cardiac amyloidosis in 2023: A review of pathophysiology, diagnosis, and treatment. Heart Fail J India 1(2):83. https:\/\/doi.org\/10.4103\/HFJI.HFJI_34_23","journal-title":"Heart Fail J India"},{"key":"10624_CR14","doi-asserted-by":"publisher","unstructured":"Panichella G, Aimo A, Castiglione V, Vergaro G, Emdin M (2025) Heart failure management in cardiac amyloidosis: towards a paradigm shift. Card Fail Rev 11. https:\/\/doi.org\/10.15420\/cfr.2024.33","DOI":"10.15420\/cfr.2024.33"},{"key":"10624_CR15","doi-asserted-by":"publisher","unstructured":"Ghazal M, Jensen E, Akkawi AR, Fancher A, Oundo E, Briasoulis A (2025) Cardiac amyloidosis: new insights into pathophysiology and therapeutic advances. Curr Probl Cardiol 50(9):103125. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103125","DOI":"10.1016\/j.cpcardiol.2025.103125"},{"key":"10624_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.amjcard.2024.10.009","volume":"236","author":"A Shchendrygina","year":"2025","unstructured":"Shchendrygina A, Mewton N, Niederseer D, Kida K, Guidetti F, Duval AJ et al (2025) Cardiac Amyloidosis Screening and Management in Patients With Heart Failure With Preserved Ejection Fraction: An International Survey. Am J Cardiol 236:42\u201348. https:\/\/doi.org\/10.1016\/j.amjcard.2024.10.009","journal-title":"Am J Cardiol"},{"key":"10624_CR17","doi-asserted-by":"publisher","unstructured":"Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O et al (2025) Changing treatment landscape in transthyretin cardiac amyloidosis. Circ Heart Fail 18(8). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012112","DOI":"10.1161\/CIRCHEARTFAILURE.124.012112"},{"issue":"4","key":"10624_CR18","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1002\/ehf2.13443","volume":"8","author":"RD Adam","year":"2021","unstructured":"Adam RD, Coriu D, Jercan A, B\u0103deli\u0163\u0103 S, Popescu BA, Damy T et al (2021) Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail 8(4):2380\u20132396. https:\/\/doi.org\/10.1002\/ehf2.13443","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10624_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.26599\/1671-5411.2023.05.006","volume":"20","author":"S Bukhari","year":"2023","unstructured":"Bukhari S (2023) Cardiac amyloidosis: state-of-the-art review. J Geriatric Cardiol 20(5):361\u2013375. https:\/\/doi.org\/10.26599\/1671-5411.2023.05.006","journal-title":"J Geriatric Cardiol"},{"issue":"3","key":"10624_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jccase.2023.04.011","volume":"28","author":"DM Rucker","year":"2023","unstructured":"Rucker DM, Siddiqi OK, Pimentel DR, Luptak I (2023) Hemodynamic testing to guide vasodilator therapy in cardiac amyloidosis. J Cardiol Cases 28(3):105\u2013108. https:\/\/doi.org\/10.1016\/j.jccase.2023.04.011","journal-title":"J Cardiol Cases"},{"issue":"5","key":"10624_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11864-020-00738-8","volume":"21","author":"AVS Macedo","year":"2020","unstructured":"Macedo AVS, Schwartzmann PV, de Gusm\u00e3o BM, de Melo MDT, Coelho-Filho OR (2020) Advances in the Treatment of Cardiac Amyloidosis. Curr Treat Options Oncol 21(5):36. https:\/\/doi.org\/10.1007\/s11864-020-00738-8","journal-title":"Curr Treat Options Oncol"},{"key":"10624_CR22","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J et al (2025) Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. JACC. https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004","DOI":"10.1016\/j.jacc.2025.09.004"},{"key":"10624_CR23","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M et al (2025) Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf710","DOI":"10.1093\/eurheartj\/ehaf710"},{"issue":"11","key":"10624_CR24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/J.JACC.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO et al (2023) 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 81(11):1076\u20131126. https:\/\/doi.org\/10.1016\/J.JACC.2022.11.022","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10624_CR25","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S et al (2024) SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol 83(24):2411\u20132422 2024.03.429 PubMed PMID: 38866445","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10624_CR26","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH (2005) Diagnosis and Management of the Cardiac Amyloidoses. Circulation 112(13):2047\u20132060. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.489187","journal-title":"Circulation"},{"issue":"4","key":"10624_CR27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK (2021) ATTR Amyloidosis: Current and Emerging Management Strategies. JACC CardioOncol 3(4):488\u2013505. https:\/\/doi.org\/10.1016\/j.jaccao.2021.06.006","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10624_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","volume":"3","author":"G Bianchi","year":"2021","unstructured":"Bianchi G, Zhang Y, Comenzo RL (2021) AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies. JACC CardioOncol 3(4):467\u2013487. https:\/\/doi.org\/10.1016\/j.jaccao.2021.09.003","journal-title":"JACC CardioOncol"},{"issue":"S1","key":"10624_CR29","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.5045\/br.2020.S007","volume":"55","author":"SH Jung","year":"2020","unstructured":"Jung SH, Jo JC, Song GY, Ahn SY, Yang DH, Ahn JS et al (2020) Frontline therapy for newly diagnosed patients with multiple myeloma. Blood Res 55(S1):S37\u201342. https:\/\/doi.org\/10.5045\/br.2020.S007","journal-title":"Blood Res"},{"key":"10624_CR30","doi-asserted-by":"publisher","unstructured":"Theodorakakou F, Dimopoulos MA, Kastritis E (2021) Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. Ther Adv Hematol 12. https:\/\/doi.org\/10.1177\/20406207211058334","DOI":"10.1177\/20406207211058334"},{"issue":"10","key":"10624_CR31","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/ejhf.2675","volume":"24","author":"A Bayes-Genis","year":"2022","unstructured":"Bayes-Genis A, Aimo A, Jhund P, Richards M, de Boer RA, Arfsten H et al (2022) Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 24(10):1767\u20131777. https:\/\/doi.org\/10.1002\/ejhf.2675","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10624_CR32","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO et al (2023) 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. J Am Coll Cardiol 81(11):1076\u20131126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10624_CR33","doi-asserted-by":"publisher","first-page":"100092","DOI":"10.1016\/j.bneo.2025.100092","volume":"2","author":"B Yohannan","year":"2025","unstructured":"Yohannan B, Rees M, Gertz MA, Dispenzieri A, Kapoor P, Buadi FK et al (2025) Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis. Blood Neoplasia 2(2):100092. https:\/\/doi.org\/10.1016\/j.bneo.2025.100092","journal-title":"Blood Neoplasia"},{"issue":"1","key":"10624_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"DR Messroghli","year":"2016","unstructured":"Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2016) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19(1):75. https:\/\/doi.org\/10.1186\/s12968-017-0389-8","journal-title":"J Cardiovasc Magn Reson"},{"key":"10624_CR35","doi-asserted-by":"publisher","unstructured":"Liu Y, Lv M, Zhong J, Li Y (2025) Cardiac magnetic resonance research advances in myocardial fibrosis of hypertrophic cardiomyopathy. Front Cardiovasc Med 12. https:\/\/doi.org\/10.3389\/fcvm.2025.1684960","DOI":"10.3389\/fcvm.2025.1684960"},{"issue":"20","key":"10624_CR36","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1182\/bloodadvances.2023010324","volume":"7","author":"JN Gustine","year":"2023","unstructured":"Gustine JN, Staron A, Mendelson L, Joshi T, Gopal DM, Siddiqi OK et al (2023) Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis. Blood Adv 7(20):6080\u20136091. https:\/\/doi.org\/10.1182\/bloodadvances.2023010324","journal-title":"Blood Adv"},{"issue":"9","key":"10624_CR37","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS (2024) Cardiac Amyloidosis Due to Transthyretin Protein. JAMA 331(9):778. https:\/\/doi.org\/10.1001\/jama.2024.0442","journal-title":"JAMA"},{"issue":"11","key":"10624_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M et al (2018) Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379(11):1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"10624_CR39","doi-asserted-by":"publisher","unstructured":"Damy T, Wang R, Maurer MS, Gillmore JD, Fontana M (2025) Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3696","DOI":"10.1002\/ejhf.3696"},{"issue":"1","key":"10624_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P, Klein AL, Fernandes F, Weissman NJ et al (2024) Effect of Tafamidis on Cardiac Function in Patients with Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. JAMA Cardiol 9(1):25\u201334 10.1001\/JAMACARDIO.2023.4147 PubMed PMID: 37966817","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10624_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S et al (2024) Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med 390(2):132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"issue":"10","key":"10624_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","volume":"85","author":"DP Judge","year":"2025","unstructured":"Judge DP, Alexander KM, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs SDJ et al (2025) Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol 85(10):1003\u20131014. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.042","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10624_CR43","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","volume":"85","author":"RM Witteles","year":"2025","unstructured":"Witteles RM, Garcia-Pavia P, Damy T, Grogan M, Sheikh FH, Morbach C et al (2025) Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy. J Am Coll Cardiol 85(20):1959\u20131970. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10624_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B et al (2025) Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med 392(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134","journal-title":"N Engl J Med"},{"issue":"6","key":"10624_CR45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jacc.2025.04.055","volume":"86","author":"MS Maurer","year":"2025","unstructured":"Maurer MS, Berk JL, Damy T, Sheikh FH, Gonz\u00e1lez-Costello J, Morbach C et al (2025) Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol 86(6):459\u2013475. https:\/\/doi.org\/10.1016\/j.jacc.2025.04.055","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10624_CR46","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2025.06.022","volume":"86","author":"KS Jering","year":"2025","unstructured":"Jering KS, Fontana M, Skali H, Bulwer BE, Prasad N, Roshanali F et al (2025) Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol 86(6):444\u2013455. https:\/\/doi.org\/10.1016\/j.jacc.2025.06.022","journal-title":"J Am Coll Cardiol"},{"key":"10624_CR47","doi-asserted-by":"publisher","unstructured":"Jering KS, Fontana M, Lairez O, Longhi S, Azevedo O, Morbach C et al (2025 Aug) Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial. Nat Med 6. https:\/\/doi.org\/10.1038\/s41591-025-03851-z","DOI":"10.1038\/s41591-025-03851-z"},{"issue":"20","key":"10624_CR48","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jacc.2025.03.454","volume":"85","author":"FH Sheikh","year":"2025","unstructured":"Sheikh FH, Habib G, Tang WHW, Gillmore JD, Egolum UO, Longhi S et al (2025) Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol 85(20):1943\u20131955. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.454","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10624_CR49","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/HCO.0000000000001156","volume":"39","author":"D Bampatsias","year":"2024","unstructured":"Bampatsias D, Wardhere A, Maurer MS (2024) Treatment of transthyretin cardiac amyloidosis. Curr Opin Cardiol 39(5):407\u2013416. https:\/\/doi.org\/10.1097\/HCO.0000000000001156","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"10624_CR50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS et al (2019) Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation 139(4):431\u2013443. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035831","journal-title":"Circulation"},{"issue":"1","key":"10624_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD (2020) Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 27(1):52\u201358. https:\/\/doi.org\/10.1080\/13506129.2019.1685487","journal-title":"Amyloid"},{"issue":"1","key":"10624_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A (2020) Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA - J Am Med Association 324(1):79\u201389 10.1001\/JAMA.2020.5493 PubMed PMID: 32633805","journal-title":"JAMA - J Am Med Association"},{"issue":"3","key":"10624_CR53","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.cjca.2019.12.002","volume":"36","author":"RM John","year":"2020","unstructured":"John RM, Stern DL (2020) Use of Implantable Electronic Devices in Patients With Cardiac Amyloidosis. Can J Cardiol 36(3):408\u2013415. https:\/\/doi.org\/10.1016\/j.cjca.2019.12.002","journal-title":"Can J Cardiol"},{"issue":"18","key":"10624_CR54","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.3390\/jcm13185588","volume":"13","author":"L Teresi","year":"2024","unstructured":"Teresi L, Trimarchi G, Liotta P, Restelli D, Licordari R, Carciotto G et al (2024) Electrocardiographic Patterns and Arrhythmias in Cardiac Amyloidosis: From Diagnosis to Therapeutic Management\u2014A Narrative Review. J Clin Med 13(18):5588. https:\/\/doi.org\/10.3390\/jcm13185588","journal-title":"J Clin Med"},{"issue":"2","key":"10624_CR55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","volume":"25","author":"E Muchtar","year":"2018","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A et al (2018) Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 25(2):86\u201392. https:\/\/doi.org\/10.1080\/13506129.2018.1449744","journal-title":"Amyloid"},{"issue":"3","key":"10624_CR56","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cjca.2019.11.039","volume":"36","author":"CC Cheung","year":"2020","unstructured":"Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK (2020) Arrhythmias in Cardiac Amyloidosis: Challenges in Risk Stratification and Treatment. Can J Cardiol 36(3):416\u2013423. https:\/\/doi.org\/10.1016\/j.cjca.2019.11.039","journal-title":"Can J Cardiol"},{"issue":"5","key":"10624_CR57","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/jcm13051300","volume":"13","author":"S Bukhari","year":"2024","unstructured":"Bukhari S, Khan SZ, Ghoweba M, Khan B, Bashir Z (2024) Arrhythmias and Device Therapies in Cardiac Amyloidosis. J Clin Med 13(5):1300. https:\/\/doi.org\/10.3390\/jcm13051300","journal-title":"J Clin Med"},{"issue":"1","key":"10624_CR58","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/heartjnl-2022-322315","volume":"110","author":"G Saturi","year":"2024","unstructured":"Saturi G, De Frutos F, Sguazzotti M, Gonzalez-Lopez E, Nardi E, Dom\u00ednguez F et al (2024) Predictors and outcomes of pacemaker implantation in patients with cardiac amyloidosis. Heart 110(1):40\u201348. https:\/\/doi.org\/10.1136\/heartjnl-2022-322315","journal-title":"Heart"},{"issue":"2","key":"10624_CR59","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mhj.2003.50","volume":"145","author":"JM Aranda","year":"2003","unstructured":"Aranda JM, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS et al (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: A prospective, randomized trial. Am Heart J 145(2):324\u2013329. https:\/\/doi.org\/10.1067\/mhj.2003.50","journal-title":"Am Heart J"},{"issue":"2","key":"10624_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.36628\/ijhf.2022.0034","volume":"5","author":"G Del Rio-Pertuz","year":"2023","unstructured":"Del Rio-Pertuz G, Benjanuwattra J, Phinyo P, Leelaviwat N, Mekraksakit P, Nair N (2023) The Mortality Benefit of Milrinone as a Continuous Outpatient Intravenous Inotrope Therapy in Advanced Heart Failure: A Systemic Review and Meta-Analysis. Int J heart Fail 5(2):106\u2013110. https:\/\/doi.org\/10.36628\/ijhf.2022.0034PubMed PMID: 37180559","journal-title":"Int J heart Fail"},{"issue":"3","key":"10624_CR61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.15420\/cfr.2019.11.2","volume":"5","author":"V Bistola","year":"2019","unstructured":"Bistola V, Arfaras-Melainis A, Polyzogopoulou E, Ikonomidis I, Parissis J (2019) Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice. Card Fail Rev 5(3):133\u2013139. https:\/\/doi.org\/10.15420\/cfr.2019.11.2","journal-title":"Card Fail Rev"},{"key":"10624_CR62","doi-asserted-by":"publisher","first-page":"100524","DOI":"10.1016\/j.ahjo.2025.100524","volume":"52","author":"AF Becerra","year":"2025","unstructured":"Becerra AF, Amanamba U, Lopez JE, Blaker NJ, Winchester DE (2025) The current use of vasoactive agents in cardiogenic shock related to myocardial infarction and acute decompensated heart failure. Am Heart J Plus: Cardiol Res Pract 52:100524. https:\/\/doi.org\/10.1016\/j.ahjo.2025.100524","journal-title":"Am Heart J Plus: Cardiol Res Pract"},{"issue":"11","key":"10624_CR63","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1253\/circj.CJ-17-1386","volume":"82","author":"H Yaku","year":"2018","unstructured":"Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E et al (2018) Demographics, Management, and In-Hospital Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary Real Clinical Practice in Japan\u2015 Observations From the Prospective, Multicenter Kyoto Congestive Heart Failure (KCHF) Registry \u2015. Circ J 82(11):2811\u20132819. https:\/\/doi.org\/10.1253\/circj.CJ-17-1386","journal-title":"Circ J"},{"issue":"4","key":"10624_CR64","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ehf2.12248","volume":"5","author":"P Martens","year":"2018","unstructured":"Martens P, Vercammen J, Ceyssens W, Jacobs L, Luwel E, Van Aerde H et al (2018) Effects of intravenous home dobutamine in palliative end-stage heart failure on quality of life, heart failure hospitalization, and cost expenditure. ESC Heart Fail 5(4):562\u2013569. https:\/\/doi.org\/10.1002\/ehf2.12248","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10624_CR65","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/ccd.28528","volume":"95","author":"A Salavitabar","year":"2020","unstructured":"Salavitabar A, Bradley EA, Chisolm JL, Hickey J, Boe BA, Armstrong AK et al (2020) Implantable pulmonary artery pressure monitoring device in patients with palliated congenital heart disease: Technical considerations and procedural outcomes. Catheter Cardiovasc Interv 95(2):270\u2013279. https:\/\/doi.org\/10.1002\/ccd.28528","journal-title":"Catheter Cardiovasc Interv"},{"key":"10624_CR66","doi-asserted-by":"publisher","unstructured":"Jakstaite AM, H\u00e4nselmann A, Soltani S, Angelini E, Heuser M, G\u00f6decke V et al (2025) Prognostic implications of right ventricular to pulmonary artery uncoupling in cardiac amyloidosis. Front Cardiovasc Med 12. https:\/\/doi.org\/10.3389\/fcvm.2025.1653950","DOI":"10.3389\/fcvm.2025.1653950"},{"issue":"3","key":"10624_CR67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cjco.2022.12.008","volume":"5","author":"J Gibson","year":"2023","unstructured":"Gibson J, McGrath K, Miller RJH, Sumner G, Clarke B (2023) Ambulatory Pulmonary Artery Pressure Monitoring Reduces Costs and Improves Outcomes in Symptomatic Heart Failure: A Single-Centre Canadian Experience. CJC Open 5(3):237\u2013249. https:\/\/doi.org\/10.1016\/j.cjco.2022.12.008","journal-title":"CJC Open"},{"key":"10624_CR68","doi-asserted-by":"publisher","unstructured":"Punnoose LR, Siddiqi H, Rosenthal J, Kittleson M, Witteles R, Alexander K (2023) Implications of extra-cardiac disease in patient selection for heart transplantation: considerations in cardiac amyloidosis. Card Fail Rev 9. https:\/\/doi.org\/10.15420\/cfr.2022.24","DOI":"10.15420\/cfr.2022.24"},{"issue":"10","key":"10624_CR69","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","volume":"43","author":"Y Peled","year":"2024","unstructured":"Peled Y, Ducharme A, Kittleson M, Bansal N, Stehlik J, Amdani S et al (2024) International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates\u20142024. J Heart Lung Transplantation 43(10):1529\u20131628e54. https:\/\/doi.org\/10.1016\/j.healun.2024.05.010","journal-title":"J Heart Lung Transplantation"},{"issue":"7","key":"10624_CR70","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3390\/jcm13071991","volume":"13","author":"M Habib","year":"2024","unstructured":"Habib M, Tiger Y, Dima D, Schl\u00f6gl M, McDonald A, Mazzoni S et al (2024) Role of Palliative Care in the Supportive Management of AL Amyloidosis\u2014A Review. J Clin Med 13(7):1991. https:\/\/doi.org\/10.3390\/jcm13071991","journal-title":"J Clin Med"},{"key":"10624_CR71","doi-asserted-by":"publisher","unstructured":"Keller DM, Straburzy\u0144ska-Migaj E, Lesiak M (2025) Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation. Polish Heart J. https:\/\/doi.org\/10.33963\/v.phj.104054","DOI":"10.33963\/v.phj.104054"},{"issue":"4","key":"10624_CR72","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s10741-025-10502-5","volume":"30","author":"SP Ang","year":"2025","unstructured":"Ang SP, Chia JE, Mukherjee D (2025) Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathy. Heart Fail Rev 30(4):759\u2013770. https:\/\/doi.org\/10.1007\/s10741-025-10502-5","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10624_CR73","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11886-024-02172-w","volume":"27","author":"AGM Patel","year":"2025","unstructured":"Patel AGM, Li P, Badrish N, Kesari A, Shah KB (2025) Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies. Curr Cardiol Rep 27(1):33. https:\/\/doi.org\/10.1007\/s11886-024-02172-w","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10624_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/hearts6030022","volume":"6","author":"RS Doyle","year":"2025","unstructured":"Doyle RS, Walsh R, Walsh J, Temperley HC, McCormick J, Giblin G (2025) Systematic Review and Meta-Analysis of Cardiac MRI T1 and ECV Measurements in Pre-Heart Failure Populations. Hearts 6(3):22. https:\/\/doi.org\/10.3390\/hearts6030022","journal-title":"Hearts"},{"issue":"10","key":"10624_CR75","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12149-025-02092-x","volume":"39","author":"O Manabe","year":"2025","unstructured":"Manabe O, Oda S, Norikane T, Aikawa T, Otaki Y, Tamaki N (2025) Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review. Ann Nucl Med 39(10):1037\u20131052. https:\/\/doi.org\/10.1007\/s12149-025-02092-x","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10624_CR76","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/jcm11092360","volume":"11","author":"RC Rimbas","year":"2022","unstructured":"Rimbas RC, Balinisteanu A, Magda SL, Visoiu SI, Ciobanu AO, Beganu E et al (2022) New Advanced Imaging Parameters and Biomarkers\u2014A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy. J Clin Med 11(9):2360. https:\/\/doi.org\/10.3390\/jcm11092360","journal-title":"J Clin Med"},{"key":"10624_CR77","doi-asserted-by":"publisher","first-page":"101207","DOI":"10.1016\/j.blre.2024.101207","volume":"66","author":"J Wang","year":"2024","unstructured":"Wang J, Li J, Zhong L (2024) Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis. Blood Rev 66:101207. https:\/\/doi.org\/10.1016\/j.blre.2024.101207","journal-title":"Blood Rev"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10624-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10624-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10624-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:59:06Z","timestamp":1775789946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10624-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10624"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10624-4","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}